[{"data":1,"prerenderedAt":221},["ShallowReactive",2],{"story-207276-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":27,"questions":28,"relatedArticles":50,"body_color":219,"card_color":220},"207276",null,"Lupus Remission Breakthrough Opens $8B+ Wellness Product Market for Sellers","- NHS CAR-T trial achieves 83% remission rate; 5M+ lupus patients worldwide signal massive demand for supportive wellness, mobility, and lifestyle products",[],[10,11,12,13,14,12,15,12,16,12,12,12,12,12,12,12,12,17,18,12,19,12,12,12,12,20,12,12,21,12,12,12,22,12,12,23,12,12,12,24,12,25,12,26],"https:\u002F\u002Fwww.knutsfordguardian.co.uk\u002Fresources\u002Fimages\u002F21037332\u002F?type=responsive-gallery-fullscreen","https:\u002F\u002Fprod-img.belfasttelegraph.co.uk\u002Fpublic\u002Fnews\u002Fuk\u002Fdwh8xh-c5348012-dab9-4558-b22e-0bdaa71c1de4-mhie-beltel-online-urn-newsml-pressassociation-io-dd7cb2c5-a984-4eff-87f0-8e0655cb9f74-featureimage.jpg\u002Falternates\u002FTHREE_TWO_1620\u002Fc5348012-dab9-4558-b22e-0bdaa71c1de4_mhie-beltel-online_urn_newsml_pressassociation_io_dd7cb2c5-a984-4eff-87f0-8e0655cb9f74-featureimage.jpg","https:\u002F\u002Fopen.http.mp.streamamg.com\u002Fp\u002F3001090\u002Fsp\u002F300109000\u002Fthumbnail\u002Fentry_id\u002F0_e0e21y15\u002Fversion\u002F100000\u002Facv\u002F132\u002Fwidth\u002F392\u002Fheight\u002F221","https:\u002F\u002Fichef.bbci.co.uk\u002Fnews\u002F480\u002Fcpsprodpb\u002Fb06d\u002Flive\u002F120b1c40-65b5-11f1-9fd1-0b44a7e33c3f.jpg.webp","https:\u002F\u002Fi.guim.co.uk\u002Fimg\u002Fmedia\u002Ff1280463c66579007896c41cf1b6f34d00813c55\u002F216_0_4685_3748\u002Fmaster\u002F4685.jpg?width=465&dpr=1&s=none&crop=none","https:\u002F\u002Fwww.greenocktelegraph.co.uk\u002Fresources\u002Fimages\u002F21037332\u002F?type=responsive-gallery-fullscreen","https:\u002F\u002Fwww.derehamtimes.co.uk\u002Fresources\u002Fimages\u002F21037332\u002F?type=responsive-gallery-fullscreen","https:\u002F\u002Fi2-prod.mirror.co.uk\u002Fincoming\u002Farticle37289171.ece\u002FALTERNATES\u002Fs1200b\u002F0_Lupus-breakthrough-treatment.jpg","https:\u002F\u002Fwww.peterboroughmatters.co.uk\u002Fresources\u002Fimages\u002F21037332\u002F?type=responsive-gallery-fullscreen","https:\u002F\u002Fstatic.independent.co.uk\u002F2026\u002F06\u002F11\u002F17\u002F01KTTM4R6TCPXP0JBZEZ6MTC81.jpg?crop=6000,3150,x0,y425&width=1200&height=630","https:\u002F\u002Fichef.bbci.co.uk\u002Face\u002Fstandard\u002F3840\u002Fcpsprodpb\u002Fb06d\u002Flive\u002F120b1c40-65b5-11f1-9fd1-0b44a7e33c3f.jpg","https:\u002F\u002Fassets.upday.com\u002F1\u002FCCuk9lGaHR0cHM6Ly9vY2RuLmV1L3B1bHNjbXMvTURBXy81NzMzN2IyOS1hNjczLTRkYTItYWI4Yy04OTU4MWMwNWE0N2YuanBlZ5GTBc0Bwsz93gABoTEE","https:\u002F\u002Fwww.hampshirechronicle.co.uk\u002Fresources\u002Fimages\u002F21037332\u002F?type=responsive-gallery-fullscreen","https:\u002F\u002Fimg-s-msn-com.akamaized.net\u002Ftenant\u002Famp\u002Fentityid\u002FAA25ql8H.img?w=768&h=512&m=6&x=409&y=150&s=212&d=212","https:\u002F\u002Fwww.sudburymercury.co.uk\u002Fresources\u002Fimages\u002F21037332\u002F?type=responsive-gallery-fullscreen","https:\u002F\u002Fwww.bromsgroveadvertiser.co.uk\u002Fresources\u002Fimages\u002F21037332\u002F?type=responsive-gallery-fullscreen","https:\u002F\u002Fwww.theboltonnews.co.uk\u002Fresources\u002Fimages\u002F21037332\u002F?type=responsive-gallery-fullscreen","A groundbreaking NHS trial at University College London Hospital has achieved an 83% remission rate (5 of 6 patients) using CAR-T cell therapy for severe lupus, marking the first successful application of cancer immunotherapy to autoimmune disease treatment. This medical breakthrough creates significant indirect e-commerce opportunities across wellness, mobility, and lifestyle product categories. Lupus affects approximately 5 million people worldwide and 69,000 UK residents, predominantly women aged 20-40, representing a high-purchasing-power demographic historically underserved by targeted product solutions.\n\n**Market Opportunity for Sellers**: The trial's success—with patient Katie Tinkler transitioning from bedridden status to skiing and dancing—demonstrates a massive addressable market for recovery-focused products. Sellers can capitalize on three distinct consumer segments: (1) Active lupus patients seeking symptom management products (compression wear, anti-inflammatory supplements, ergonomic fitness equipment); (2) Post-treatment recovery buyers purchasing mobility aids, joint support products, and wellness subscriptions; (3) Preventive health consumers influenced by the trial's visibility, driving demand for immune-support supplements, medical-grade skincare, and wellness tracking devices.\n\n**Category Expansion Signals**: The news indicates growing consumer awareness of autoimmune disease management, extending beyond lupus to multiple sclerosis and rheumatoid arthritis treatments in clinical trials. This signals emerging demand for: adaptive apparel (moisture-wicking, joint-friendly designs), medical-grade compression products, premium supplement lines (turmeric, omega-3, vitamin D formulations), wellness technology (wearable health trackers, telehealth platforms), and lifestyle products (ergonomic furniture, pain management devices). UK and EU markets show particular receptivity given NHS endorsement and EULAR (European League Against Rheumatism) conference presentation, establishing clinical credibility that drives consumer trust in related product categories.\n\n**Seller Action Timeline**: Immediate opportunities exist for sellers in health\u002Fwellness categories to develop targeted product lines and marketing campaigns leveraging the trial's visibility. The 11-month average follow-up period and ongoing clinical studies (3-5 year remission tracking) create sustained consumer interest windows. Sellers should monitor regulatory approvals—CAR-T therapy (obecabtagene autoleucel) already approved for blood cancers suggests potential NHS\u002FEU market authorization within 12-24 months, accelerating patient population growth and product demand. Regional focus on UK and EU markets offers first-mover advantage before US FDA approval and broader global expansion.",[29,32,35,38,41,44,47],{"title":30,"answer":31,"author":5,"avatar":5,"time":5},"What is CAR-T cell therapy and why does the lupus trial matter for product sellers?","CAR-T (chimeric antigen receptor T-cell) therapy genetically modifies a patient's T cells to target disease-causing B cells, effectively resetting the immune system. The NHS trial achieved 83% remission (5 of 6 patients) after 11 months, with one patient remaining medication-free after 32 years of severe lupus. For sellers, this breakthrough signals a shift from chronic disease management (ongoing medication purchases) to recovery-focused products—compression wear, mobility aids, wellness supplements, and adaptive apparel. The trial's credibility (presented at EULAR European Congress) drives consumer trust in related health categories, creating immediate demand for supportive products targeting the 5M+ global lupus patient population, predominantly women aged 20-40.",{"title":33,"answer":34,"author":5,"avatar":5,"time":5},"Which product categories should sellers prioritize given the lupus trial results?","Three high-opportunity categories emerge: (1) Recovery & Mobility Products—compression wear, joint support braces, ergonomic furniture, and pain management devices for post-treatment patients transitioning from bedridden to active lifestyles (like patient Katie Tinkler's progression to skiing); (2) Immune Support Supplements—turmeric, omega-3, vitamin D, and specialized formulations targeting autoimmune disease management; (3) Adaptive Apparel—moisture-wicking, joint-friendly clothing designed for women managing chronic inflammation. Secondary opportunities include wellness technology (health trackers, telehealth platforms) and medical-grade skincare targeting inflammation-prone skin. UK and EU sellers have first-mover advantage given NHS endorsement and EULAR conference visibility.",{"title":36,"answer":37,"author":5,"avatar":5,"time":5},"Are there supply chain or sourcing opportunities related to this medical breakthrough?","Yes, three sourcing angles emerge: (1) Medical Device Manufacturing—compression wear, joint support products, and ergonomic devices require specialized materials (moisture-wicking fabrics, medical-grade compression levels); (2) Supplement Formulation—immune-support supplements targeting autoimmune disease require specialized ingredients (turmeric, omega-3, vitamin D) and quality certifications (GMP, third-party testing); (3) Adaptive Apparel Production—women's clothing designed for joint mobility and inflammation management requires pattern innovation and fabric selection. UK and EU sellers should prioritize sourcing from certified medical device suppliers and supplement manufacturers to capitalize on NHS\u002FEULAR credibility. Chinese manufacturers (Alibaba, Global Sources) offer cost-effective production for adaptive apparel and supplements, while European suppliers provide premium positioning for medical-grade products.",{"title":39,"answer":40,"author":5,"avatar":5,"time":5},"How might regulatory approvals for CAR-T therapy affect e-commerce product demand?","CAR-T therapy approval timelines directly impact product demand cycles. The therapy is already approved for blood cancers (leukaemias, lymphomas), suggesting regulatory pathways are established. Potential NHS\u002FEU approval for lupus within 12-24 months would accelerate patient population growth from current 69,000 UK residents to potentially 200,000+ as treatment becomes available. This creates three demand phases: (1) Pre-Approval (current)—awareness-driven demand for symptom management and wellness products; (2) Post-Approval (12-24 months)—recovery-focused products as patient populations expand; (3) Mature Market (3+ years)—sustained demand for lifestyle and preventive health products. Sellers should monitor NICE (UK) and EMA (EU) approval announcements and adjust inventory\u002Fmarketing accordingly. US FDA approval would further expand addressable market to 5M+ global lupus patients.",{"title":42,"answer":43,"author":5,"avatar":5,"time":5},"How long will consumer demand for lupus-related products remain elevated?","The trial's 11-month average follow-up period and ongoing 3-5 year remission tracking create sustained interest windows. Clinical studies for multiple sclerosis and rheumatoid arthritis (mentioned in the news) suggest expanding awareness of autoimmune disease treatment beyond lupus. Regulatory approval timelines matter: CAR-T therapy (obecabtagene autoleucel) is already approved for blood cancers, suggesting potential NHS\u002FEU authorization within 12-24 months. This accelerates patient population growth and extends product demand cycles. Sellers should expect elevated search volume and consumer engagement for 18-36 months as clinical trials progress and patient populations expand across UK, EU, and eventually US markets.",{"title":45,"answer":46,"author":5,"avatar":5,"time":5},"What marketing angles can sellers use to reach lupus patients and their families?","Leverage the trial's patient success stories—Katie Tinkler's transformation from bedridden to active (skiing, dancing) resonates with lupus patients seeking lifestyle recovery products. Marketing angles include: 'Recovery-Ready Products for Autoimmune Warriors,' 'Mobility Solutions for Lupus Remission,' and 'Wellness Products Trusted by NHS Patients.' Target women aged 20-50 on health\u002Fwellness platforms, rheumatology forums, and social media communities (Instagram, TikTok) where autoimmune disease awareness is high. Emphasize clinical credibility by referencing EULAR conference presentation and NHS trial results. Partner with patient advocacy groups (Lupus UK, American Lupus Society) for authentic endorsements. Content strategy should focus on symptom management, recovery timelines, and lifestyle restoration—topics directly addressed in the trial news.",{"title":48,"answer":49,"author":5,"avatar":5,"time":5},"What competitive advantages do sellers have in this emerging market segment?","Early-mover sellers can establish brand authority in autoimmune disease wellness before major retailers (Amazon, Walmart) develop dedicated categories. Competitive advantages include: (1) Niche Positioning—targeting specific autoimmune conditions (lupus, RA, MS) with specialized products rather than generic wellness; (2) Community Building—engaging patient advocacy groups and online communities for authentic endorsements; (3) Clinical Credibility—referencing NHS trials and EULAR conference data in product descriptions and marketing; (4) Adaptive Design—developing products specifically for joint mobility, inflammation management, and recovery timelines; (5) Regional Focus—UK\u002FEU sellers can leverage NHS endorsement before US market saturation. Sellers should file for trademark protection on disease-specific product lines and establish partnerships with patient organizations to build defensible market positions before category consolidation.",[51,56,59,62,65,69,72,75,78,81,84,87,90,93,96,99,102,105,108,111,114,118,122,125,128,132,135,138,141,144,147,150,153,156,159,162,165,168,171,174,177,181,184,188,191,194,197,200,203,206,209,212,216],{"id":52,"title":53,"source":54,"logo":12,"time":55},1067646,"Patients given ‘immune reset’ treatment on NHS go into remission","https:\u002F\u002Fwww.burymercury.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission","1H AGO",{"id":57,"title":53,"source":58,"logo":24,"time":55},1067647,"https:\u002F\u002Fwww.sudburymercury.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":60,"title":53,"source":61,"logo":5,"time":55},1067648,"https:\u002F\u002Fwww.thewestonmercury.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":63,"title":53,"source":64,"logo":10,"time":55},1067649,"https:\u002F\u002Fwww.knutsfordguardian.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":66,"title":67,"source":68,"logo":5,"time":55},1067642,"'I've never been this good' – revolutionary immune reset puts lupus in remission","https:\u002F\u002Fwww.aol.com\u002Farticles\u002Five-never-good-revolutionary-immune-233119088.html",{"id":70,"title":53,"source":71,"logo":12,"time":55},1067643,"https:\u002F\u002Fwww.bournemouthecho.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":73,"title":53,"source":74,"logo":12,"time":55},1067644,"https:\u002F\u002Fwww.swindonadvertiser.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":76,"title":53,"source":77,"logo":12,"time":55},1067645,"https:\u002F\u002Fwww.hexham-courant.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":79,"title":53,"source":80,"logo":12,"time":55},1067640,"https:\u002F\u002Fwww.eadt.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":82,"title":53,"source":83,"logo":25,"time":55},1067641,"https:\u002F\u002Fwww.bromsgroveadvertiser.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":85,"title":53,"source":86,"logo":12,"time":55},1067657,"https:\u002F\u002Fwww.dunfermlinepress.com\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":88,"title":53,"source":89,"logo":12,"time":55},1067658,"https:\u002F\u002Fwww.thenorthernecho.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":91,"title":53,"source":92,"logo":12,"time":55},1067659,"https:\u002F\u002Fwww.sloughobserver.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":94,"title":53,"source":95,"logo":12,"time":55},1067653,"https:\u002F\u002Fwww.basingstokegazette.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":97,"title":53,"source":98,"logo":5,"time":55},1067654,"https:\u002F\u002Fwww.ayradvertiser.com\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":100,"title":53,"source":101,"logo":5,"time":55},1067655,"https:\u002F\u002Fwww.andoveradvertiser.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":103,"title":53,"source":104,"logo":12,"time":55},1067656,"https:\u002F\u002Fwww.cravenherald.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":106,"title":53,"source":107,"logo":12,"time":55},1067650,"https:\u002F\u002Fwww.clydebankpost.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":109,"title":53,"source":110,"logo":11,"time":55},1067651,"https:\u002F\u002Fwww.belfasttelegraph.co.uk\u002Fnews\u002Fuk\u002Fpatients-given-immune-reset-treatment-on-nhs-go-into-remission\u002Fa\u002F156920161.html",{"id":112,"title":53,"source":113,"logo":12,"time":55},1067652,"https:\u002F\u002Fwww.asianimage.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":115,"title":116,"source":117,"logo":19,"time":55},1067628,"Groundbreaking therapy could revolutionise treatment for lupus","https:\u002F\u002Fwww.the-independent.com\u002Fbulletin\u002Fnews\u002Flupus-treatment-nhs-cart-therapy-b2994402.html",{"id":119,"title":120,"source":121,"logo":21,"time":55},1067629,"From bedridden to skiing: Lupus patient's life transformed by cancer therapy in UK first","https:\u002F\u002Fwww.upday.com\u002Fuk\u002Fuknews\u002Ffrom-bedridden-to-skiing-lupus-patients-life-transformed-by-cancer-therapy-in-uk\u002F30svtyx",{"id":123,"title":53,"source":124,"logo":12,"time":55},1067668,"https:\u002F\u002Fwww.newsandstar.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":126,"title":53,"source":127,"logo":12,"time":55},1067669,"https:\u002F\u002Fwww.thenational.scot\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":129,"title":130,"source":131,"logo":14,"time":55},1067626,"Lupus patients in England in remission after pioneering NHS trial of GM therapy","https:\u002F\u002Fwww.theguardian.com\u002Fscience\u002F2026\u002Fjun\u002F12\u002Flupus-patients-in-remission-england-nhs-trial-genentically-modified-t-cell-therapy",{"id":133,"title":67,"source":134,"logo":13,"time":55},1067627,"https:\u002F\u002Fwww.bbc.com\u002Fnews\u002Farticles\u002Fc4gy2d9y5z3o",{"id":136,"title":53,"source":137,"logo":12,"time":55},1067664,"https:\u002F\u002Fwww.stirlingnews.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":139,"title":53,"source":140,"logo":12,"time":55},1067665,"https:\u002F\u002Fwww.readingchronicle.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":142,"title":53,"source":143,"logo":12,"time":55},1067666,"https:\u002F\u002Fwww.yorkpress.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":145,"title":53,"source":146,"logo":12,"time":55},1067667,"https:\u002F\u002Fwww.wirralglobe.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":148,"title":53,"source":149,"logo":5,"time":55},1067660,"https:\u002F\u002Fwww.lowestoftjournal.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":151,"title":53,"source":152,"logo":15,"time":55},1067661,"https:\u002F\u002Fwww.greenocktelegraph.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":154,"title":53,"source":155,"logo":12,"time":55},1067662,"https:\u002F\u002Fwww.whitehavennews.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":157,"title":53,"source":158,"logo":12,"time":55},1067663,"https:\u002F\u002Fwww.thetelegraphandargus.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":160,"title":53,"source":161,"logo":12,"time":55},1067670,"https:\u002F\u002Fwww.becclesandbungayjournal.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":163,"title":53,"source":164,"logo":12,"time":55},1067639,"https:\u002F\u002Fwww.glasgowtimes.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":166,"title":67,"source":167,"logo":20,"time":55},1067635,"https:\u002F\u002Fwww.bbc.co.uk\u002Fnews\u002Farticles\u002Fc4gy2d9y5z3o",{"id":169,"title":53,"source":170,"logo":5,"time":55},1067636,"https:\u002F\u002Fwww.ilkleygazette.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":172,"title":53,"source":173,"logo":26,"time":55},1067637,"https:\u002F\u002Fwww.theboltonnews.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":175,"title":53,"source":176,"logo":18,"time":55},1067638,"https:\u002F\u002Fwww.peterboroughmatters.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":178,"title":179,"source":180,"logo":17,"time":55},1067631,"Lupus put in remission by revolutionary immune system treatment","https:\u002F\u002Fwww.mirror.co.uk\u002Fnews\u002Fhealth\u002Flupus-put-remission-revolutionary-immune-37289076",{"id":182,"title":53,"source":183,"logo":12,"time":55},1067675,"https:\u002F\u002Fwww.helensburghadvertiser.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":185,"title":186,"source":187,"logo":5,"time":55},1067632,"‘It’s miraculous’: Groundbreaking NHS immune therapy sees lupus patients go into remission","https:\u002F\u002Fwww.aol.com\u002Farticles\u002Fgroundbreaking-nhs-treatment-sees-patients-230100000.html",{"id":189,"title":53,"source":190,"logo":12,"time":55},1067676,"https:\u002F\u002Fwww.messengernewspapers.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":192,"title":53,"source":193,"logo":23,"time":55},1067633,"https:\u002F\u002Fwww.msn.com\u002Fen-gb\u002Fhealth\u002Fother\u002Fpatients-given-immune-reset-treatment-on-nhs-go-into-remission\u002Far-AA25pTrd",{"id":195,"title":53,"source":196,"logo":12,"time":55},1067677,"https:\u002F\u002Fwww.timesandstar.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":198,"title":53,"source":199,"logo":5,"time":55},1067634,"https:\u002F\u002Fuk.news.yahoo.com\u002Fpatients-given-immune-reset-treatment-230001916.html",{"id":201,"title":53,"source":202,"logo":12,"time":55},1067678,"https:\u002F\u002Fwww.runcornandwidnesworld.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":204,"title":53,"source":205,"logo":22,"time":55},1067671,"https:\u002F\u002Fwww.hampshirechronicle.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":207,"title":53,"source":208,"logo":16,"time":55},1067672,"https:\u002F\u002Fwww.derehamtimes.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":210,"title":53,"source":211,"logo":12,"time":55},1067673,"https:\u002F\u002Fwww.theoldhamtimes.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission",{"id":213,"title":214,"source":215,"logo":5,"time":55},1067630,"CAR T-cell therapy shows early promise in severe lupus | UCL News - UCL","https:\u002F\u002Fwww.ucl.ac.uk\u002Fnews\u002F2026\u002Fjun\u002Fcar-t-cell-therapy-shows-early-promise-severe-lupus",{"id":217,"title":53,"source":218,"logo":12,"time":55},1067674,"https:\u002F\u002Fwww.ipswichstar.co.uk\u002Fnews\u002Fnational\u002F26187806.patients-given-immune-reset-treatment-nhs-go-remission","#d030f2ff","#d030f24d",1781357513382]